CXCL10 and neoplasm: These results indicated that the rMV-SLAMblind treatment induces the expression of CXCL10 both from tumor cells and non-tumor cells infiltrating in tumor tissue and IL12a from non-tumor cells, which possibly contributes to recruit and activate NK cells.